Impact of organ confined prostate cancer treatment on quality of life.

Prostate cancer (PCa) is the second most common male cancer in the world. Its incidence is estimated to grow to 1.7 million new cases and 499,000 new deaths by 2030. Treatment of OCPC can affect patients physically and mentally, as well as their close relationships and their job or career, which conditions health-related quality of life (QoL).

Evaluate the impact on QoL attributable to the treatment for Organ Confined Prostate Cancer (OCPC).

Prospective multicenter observational study of 406 patients with OCPC treated from January 2015 to June 2018. The sample was divided into four study groups, according to the type of treatment: radical prostatectomy (RP) (GA), external radiotherapy (ERT) (GB), brachytherapy (BT) (GC) and other treatments different from monotherapy with RP, ERT or BT (GD).

The age in GC was lower, the mean Prostate Specific Antigen (PSA) of all patients was 8.13 ng/ml, the group with the highest mean PSA was GB with a mean of 10.43 ng/dL, the mean Tumor Stage (TNM) was 3.82, and GD had the lowest post treatment quality of life.

OCPC treatment affects QoL. Curative monotherapies, specifically RP and BT, have less effect on QoL than external radiotherapy or other therapeutic alternatives. Urinary incontinence and fistulas secondary to OCPC have the highest impact on QOL impairment. The internationally validated SF 36 questionnaire is a useful cross-sectional measure of QOL to compare the impact of OCPC treatment modalities.

Actas urologicas espanolas. 2020 Sep 16 [Epub ahead of print]

A Alvarez-Ossorio-Rodal, B Padilla-Fernandez, C A Muller-Arteaga, F Miglioni, J L Alvarez-Ossorio-Fernandez, S Valverde-Martínez, M T Marquez-Sanchez, M C Flores-Fraile, N A Linares-Mesa, J A Miron-Canelo, M B Garcia-Cenador, M F Lorenzo-Gomez

Departamento de Cirugía de la Universidad de Salamanca, Salamanca, España., Departamento de Cirugía de la Universidad de La Laguna, Tenerife, España., Servicio de Urología del Hospital Universitario de Ourense, Orense, España., Departamento de Urología, Azienda Ospedaliera Universitaria Integrata, Verona, Italia., Servicio de Urología del Hospital Universitario Puerta del Mar, Cádiz, España., Servicio de Urología del Hospital Universitario de Ávila, Ávila, España; Grupo de Investigación Multidisciplinar Urológico de Renal (GRUMUR) del Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España., Grupo de Investigación Multidisciplinar Urológico de Renal (GRUMUR) del Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España., Departamento de Cirugía de la Universidad de Salamanca, Salamanca, España. Electronic address: ., Servicio de Radioterapia del Hospital Universitario Juan Ramón Jiménez, Huelva, España., Grupo de Investigación Multidisciplinar Urológico de Renal (GRUMUR) del Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España; Departamento de Ciencias Biomédicas y del Diagnóstico de la Universidad de Salamanca, Salamanca, España., Departamento de Cirugía de la Universidad de Salamanca, Salamanca, España; Grupo de Investigación Multidisciplinar Urológico de Renal (GRUMUR) del Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España; Servicio de Urología del Hospital Universitario de Salamanca, Salamanca, España.